{"id":"W2223384622","doi":"10.1158/1538-7445.sabcs14-p1-13-07","title":"Abstract P1-13-07: A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Tolerability; Antiestrogen; Aromatase inhibitor; Oncology; Clinical endpoint; Cancer; Population; Adverse effect; Randomized controlled trial; Tamoxifen; Gynecology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00175683,0.0004551774,0.0009144425,0.0002494199,0.0002964277,0.00007262754,0.000333476,0.0001134918,0.00009933132],"category_scores_gemma":[0.0003744051,0.0002524788,0.00009256327,0.000671712,0.0004405887,0.0003883026,0.0001312173,0.0007597154,0.000001216101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005944368,"about_ca_system_score_gemma":0.002351495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006252374,"about_ca_topic_score_gemma":0.00098721,"domain_scores_codex":[0.995692,0.0001450804,0.0008577342,0.0009127092,0.001316351,0.001076107],"domain_scores_gemma":[0.9969039,0.000731577,0.0002950662,0.0007178276,0.0004473365,0.0009043195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5363599,0.004083447,0.1247832,0.000352803,0.0007998056,0.0005721673,0.009517965,0.0002187577,0.01441905,0.000004446114,0.00004321375,0.3088452],"study_design_scores_gemma":[0.3575541,0.05573043,0.4885982,0.004366577,0.0003822289,0.00008428487,0.08806805,0.0003313418,0.00223548,0.0001186949,0.001332949,0.001197649],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873041,0.003696312,0.000002740811,0.00207198,0.0002543451,0.006018468,0.0005967339,0.00005196081,0.000003345516],"genre_scores_gemma":[0.9945878,0.0003800688,0.0001669786,0.00007388946,0.0004945265,0.004114616,0.00003545408,0.0001163614,0.00003028455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3638149,"threshold_uncertainty_score":0.9999927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08213161146119569,"score_gpt":0.4780968770809828,"score_spread":0.3959652656197871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}